Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Allogene Therapeutics
company
About
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
- 101 - 250
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $411.77M
- Industries
- Biotechnology,Health Diagnostics,Pharmaceutical
- Founded date
- Jan 1, 2017
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$531.77M
Allogene Therapeutics has raised a total of
$531.77M
in funding over 2 rounds. Their latest funding was raised on
Sep 7, 2018 from a Convertable Note round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Sep 7, 2018 | Convertable Note | $120M | 1 | — | — | Detail |
| Apr 19, 2018 | Series A | $411.77M | 2 |
TPG
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Allogene Therapeutics is funded by 3 investors.
TPG
and venBio Select Advisor
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
TPG
|
Yes | Series A |
venBio Select Advisor
|
— | Convertable Note |
Pfizer
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
